Matsuda, Satoru

写真a

Affiliation

School of Medicine, Department of Surgery (General and Gastroenterological Surgery) ( Shinanomachi )

Position

Professor
Scopus Paper Info  
Paper Count: 197 Citation Count: 3593 h-index: 28

Click to view the Scopus page. The data was downloaded from Scopus API in May 17, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲
 

Papers 【 Display / hide 】

  • Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU)

    Sakanaka K., Sasaki K., Tsushima T., Machida R., Hamai Y., Watanabe A., Kawabata K., Matsuda S., Kato K., Fukuda H., Takeuchi H.

    BMC Cancer 26 ( 1 )  2026.12

    　View Summary

    Background: The immunogenic cell death induced by radiotherapy (RT) has been demonstrated to enhance the systemic antitumor effect of immune checkpoint inhibitors (ICIs). The incorporation of RT into ICIs has the potential to mitigate the occurrence of early treatment failure, particularly with dual ICI combination, in patients with advanced or recurrent esophageal cancer. Methods: This randomized phase II trial, initiated in November 2024, aims to explore the superiority of the combination of RT with nivolumab plus ipilimumab over nivolumab plus ipilimumab alone in patients with advanced or recurrent esophageal squamous cell carcinoma. The primary endpoint is progression-free survival, while the secondary endpoints include overall survival, response rate, duration of response, and adverse events. We assumed a 6-month PFS of 35% in the nivolumab plus ipilimumab alone arm and expected a 15% increase in the 6-month PFS for the RT with nivolumab plus ipilimumab arm (HR, 0.66). The total required sample size was calculated to be 70 (35 per arm) to achieve a desired power of 80% with an overall one-sided alpha of 20%, an accrual period of 2.5 years, and a follow-up period of 1 year. A total of 74 patients will be enrolled from 41 institutions in Japan. An ancillary study analyzes cytokine profiles and phenotypic characteristics in peripheral blood mononuclear cells during treatment with the protocol. Discussion: The objective of this trial is to assess the safety and efficacy of RT in combination with dual ICIs in reducing early treatment failure and improving outcomes with translational research. Findings from this trial will inform a future phase III trial in this patient population. Trial registration: This trial has been registered on November 5th, 2024, in the Japan Registry of Clinical Trials as jRCT1031240461 (https://jrct.mhlw.go.jp/en-latest-detail/jRCT1031240461).

  • Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma

    Okui J., Matsuda S., Nagashima K., Sato Y., Kawakubo H., Ruhstaller T., Thuss-Patience P., Nilsson M., Klevebro F., Tan L., Zhang S., Aparicio T., Piessen G., Van der Zijden C., Mostert B., Wijnhoven B.P.L., Tsushima T., Takeuchi H., Kato K., Kitagawa Y.

    British Journal of Surgery 113 ( 3 )  2026.03

    ISSN  00071323

    　View Summary

    Background: Although several oesophageal squamous cell carcinoma (OSCC) studies have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pCR rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate endpoint, it remains uncertain whether survival differs between these modalities among patients with OSCC who achieve pCR. Methods: An integrated analysis of individual patient data (IPD) from phase III trials evaluating perioperative therapies for resectable OSCC was conducted, emphasizing prognostic differences between NAC and NACRT, particularly among patients who achieved pCR. Results: IPD from seven phase III RCTs across six countries included data for 1044 patients with OSCC (83.5% male; mean age of 62.3 years). Of these patients, 605 (58.0%) received NAC and 439 (42.0%) received NACRT, with R0 resection rates of 89.6% versus 84.7% and pCR rates of 6.9% versus 34.2% respectively. Among patients who achieved pCR (192 patients), 5-year OS was 97.5% in the NAC group and 70.4% in the NACRT group, while 5-year recurrence-free survival was 80.8% and 63.7% respectively. Multivariable analysis demonstrated a significant survival advantage for NAC among patients who achieved pCR. Conclusion: Among patients who achieved pCR, postoperative outcomes varied considerably by neoadjuvant treatment modality. The markedly favourable prognosis associated with pCR after NAC suggests that these patients may represent an optimal candidate cohort for future evaluation of surgery-avoidance and watch-and-wait strategies.

  • Additional treatment for esophageal cancer patients with incomplete resection due to the surrounding organ invasion: a nationwide survey of 45 Japanese centers

    Okamura A., Watanabe M., Okui J., Matsuda S., Hamai Y., Takahashi N., Sato S., Abe T., Ishida H., Goto H., Bamba T., Kakishita T., Booka E., Kitagami H., Kuwabara S., Kimura Y., Kosumi K., Matsumoto S., Nakajima M., Inoue S., Kitagawa H., Shibasaki S., Sadanaga N., Takebayashi K., Shichinohe T., Kawakubo H., Kakeji Y., Kono K., Kitagawa Y., Takeuchi H.

    Esophagus 23 ( 1 ) 88 - 98 2026.01

    ISSN  16129059

    　View Summary

    Background: We occasionally experience incomplete resection of esophageal cancer due to the surrounding organ invasion. The efficacy of additional treatment in these cases is unknown. Methods: We studied 445 patients with esophageal squamous cell carcinoma who were unable to undergo curative esophagectomy due to cancer invasion to the surrounding organs at 45 esophageal centers in Japan. Survival outcomes were compared based on the additional treatment modalities. Results: Postoperatively, 175 (40.0%) received no additional treatment, while 59 (13.5%), 153 (35.0%), and 50 (11.4%) received additional chemotherapy, chemoradiotherapy, or radiotherapy, respectively. The three-year disease progression and overall survival rates were 90.6% (95% confidence interval 87.2–93.1%) and 15.4% (95% confidence interval 12.2–19.3%), respectively. Multivariable analysis revealed that chemotherapy, chemoradiotherapy, and radiotherapy were all independently associated with reduced disease progression (hazard ratios [95% confidence intervals]: 0.57 [0.40–0.81], 0.52 [0.39–0.69], and 0.48 [0.33–0.72], respectively). Meanwhile, additional treatment with chemotherapeutic agents (chemotherapy and chemoradiotherapy) was independently associated with better overall survival (hazard ratios [95% confidence intervals]: 0.51 [0.35–0.73] and 0.59 [0.44–0.79], respectively); however, radiotherapy alone had a limited impact (hazard ratio [95% confidence interval]: 0.74 [0.50–1.10]). Conclusions: Any additional treatment could suppress disease progression after incomplete resection, but radiotherapy alone has a limited effect. Additional systemic chemotherapeutics may increase patient survival.

  • Impact of prophylactic drain placement on intra-abdominal infections after gastrectomy: nationwide inpatient database study in Japan

    Kouzu K., Aso S., Hirano Y., Matsui H., Fushimi K., Kitagawa H., Kato T., Yamane N., Hagiwara O., Miyoshi N., Matsuda S., Maruyama H., Morikane K., Sasaki J., Yasunaga H., Kitagawa Y., Tsujimoto H.

    Gastric Cancer 29 ( 1 ) 230 - 237 2026.01

    ISSN  14363291

    　View Summary

    Objective: This study aimed to evaluate the impact of drain placement on the incidence of postoperative complications in patients undergoing gastrectomy. Background: The effectiveness of prophylactic abdominal drain placement in gastrectomy remains unclear. Nevertheless, they are still commonly used following gastrectomy. Methods: We conducted a retrospective cohort study using a nationwide inpatient database in Japan. Patients who underwent gastrectomy for gastric cancer between January 2014 and March 2022 were included. We applied overlap weighting based on propensity scores to adjust for baseline characteristics. The primary outcome was the incidence of intra-abdominal infections. Secondary outcomes included postoperative percutaneous drainage, in-hospital death, length of hospital stay, and total hospitalization costs. Results: A total of 217,750 patients met the inclusion criteria, and 196,660 (90.3%) received prophylactic abdominal drains. After overlap weighting, the drain group had a significantly lower incidence of intra-abdominal infections compared to the no-drain group (6.3% vs. 7.6%; 95% confidence interval [CI] − 1.7 to − 1.0). The prophylactic drains were also associated with reduced in-hospital postoperative mortality (0.6% vs. 0.8%; 95% CI − 0.3 to − 0.1). No significant differences were observed between the two groups in postoperative percutaneous drainage or hospital stay duration. Conclusion: This study suggests that prophylactic abdominal drainage was associated with a reduced incidence of intra-abdominal infections after gastrectomy without increasing hospitalization duration or medical costs.

  • Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314

    Matsuda S., Tsushima T., Kawakubo H., Hironaka S., Tsubosa Y., Sakanaka K., Oguma J., Kadowaki S., Tsunoda S., Hara H., Koyanagi K., Yamaguchi T., Harada K., Takahashi M., Minashi K., Baba E., Sasaki K., Machida R., Takeuchi H.

    Esophagus 23 ( 1 ) 111 - 119 2026.01

    ISSN  16129059

    　View Summary

    Background: Recent advances in multimodal treatments indicate that conversion therapy (CT) is a viable option for metastatic esophageal cancer (EC). JCOG1314 was a randomized phase III trial to confirm the survival benefit of docetaxel plus cisplatin plus 5-fluorouracil (DCF) versus cisplatin plus 5-fluorouracil (CF) for metastatic EC. The purpose of this analysis was to evaluate the safety and survival of CT in patients enrolled in JCOG1314. Methods: CT was defined as surgery or chemoradiotherapy (CRT) aimed at cure following initial treatment for tumors that were initially unresectable because of distant metastasis. Clinicopathological factors, surgical outcomes, toxicities during CRT, and survival were compared between the CT and non-CT groups. Results: Of 240 patients enrolled in JCOG1314, excluding patients with recurrent disease, 154 with initially unresectable EC because of distant metastasis were selected. Of these patients, 21 received CT, which included conversion surgery (n = 5) and conversion CRT (n = 16). There was no significant difference in the number of metastatic organs or chemotherapy regimen between the CT and non-CT groups. The most common M1 factor in the CT group was the thoracic lymph node. The 3-year overall survival (OS) for the CT and non-CT groups was 52.4 and 14.3%, respectively. Multivariable analysis revealed that CT patients showed significantly better OS compared with the non-CT group (HR 0.36, 95% CI 0.19–0.67, p < 0.01). Conclusion: CT may be safely performed with a favorable prognosis in EC. A prospective study is warranted to determine whether CT improves survival in metastatic EC.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • リキッドバイオプシーとAI画像診断による多角的腫瘍モニタリング手法確立

    2024.04
    -
    2027.03

    基盤研究(C), Principal investigator

  • 食道癌における手術回避を目指した腫瘍と宿主の双方向性モニタリング手法確立

    2022.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 若手研究, Principal investigator

  • 食道癌におけるリキッドバイオプシーを用いた手術回避を目指した治療開発

    2020.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists , Principal investigator

  • 腫瘍微小環境における細胞老化を介した食道癌に対する集学的治療抵抗性機序の解明

    2019.08
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Research Activity Start-up , Principal investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • SURGICAL ONCOTHERAPY: PRACTICE

    2026

  • LECTURE SERIES, SURGERY

    2026

  • CLINICAL CLERKSHIP IN GENERAL AND GASTROINTESTINAL SURGERY

    2026

  • ADVANCED SURGICAL ONCOTHERAPY

    2026

  • SURGERY

    2026

display all >>

Page Top ▲